API | sotagliflozin

sotagliflozin Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Now

Sotagliflozin, sold under the brand name Zynquista, is a drug approved in the European Union for people with type 1 diabetes. ^Wikipedia

Chemistry

SMILES: CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]3O[C@H](SC)[C@@H](O)[C@H](O)[C@H]3O)cc1
InChIKey: QKDRXGFQVGOQKS-CRSSMBPESA-N
Mol. Mass: 424.95
ALogP: 3.17 Partition coefficient
ChEMBL Molecule:
sotagliflozin

More Chemistry

Pharmacology

Mechanisms of Action:
- Sodium/glucose cotransporter 1 (Homo sapiens) ^UniProt
- Sodium/glucose cotransporter 2 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

(2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol | lp-802034 | lx4211 | lx-4211 | sotagliflozin

Organizations (3)

Research & Development (3)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (10)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (10)

Blood Glucose (Phase 3)

Chronic Kidney Disease-Mineral and Bone Disorder (Phase 3)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 1 (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Healthy Volunteers (Phase 1)

Heart Failure (Phase 3)

Kidney Failure, Chronic (Phase 1)

Liver Diseases (Phase 1)

Renal Insufficiency, Chronic (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 46
# of Trial Organizations: 3

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue